Sturm, Ruger & Company is rated a Buy as it anticipates strong earnings in the third quarter of 2026, driven by a 19% year-over-year sales increase and positive US gun check trends. The company is gaining market share with premium products making up 29% of sales. Its strategic 25% stake by Beretta enhances international reach and potential synergies, supporting long-term growth beyond current forecasts. Despite a valuation premium, the partnership and strong industry demand suggest further upside potential.
Sturm, Ruger's strategic alliance with Beretta is noted here alongside Pluang's Consumer Cyclical sector data. For readers following this sector, as of Oct 26, 2026 12:01 WIB, 67 of 134 US stocks rose while 63 fell. Kohl's Corporation gained 9.07% to USD 24.17 with a typical hold time of 48 days, contrasting with Newegg Commerce Inc's 8.14% drop to USD 9.70 and a much shorter hold time of 15 days. PulteGroup, Inc. also rose 8.29% to USD 122.25, held typically for 91 days.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
